Krsnaa Diagnostics Approves 16.21 Lakh Promoter Warrants At ₹565 Floor

Q1 FY27 Consolidated Results YoY: Revenue at 236 Cr vs 193 Cr, up 22.0%. EBITDA at 65.2 Cr vs 55.4 Cr, up 17.8%. EBITDA Margin at 27.7% vs 28.7%, contraction of 100bps; fees to hospitals and others grew 164% vs revenue growth of 22%, while Other Income rose 83% to 7.2 Cr from 4.0 Cr. PAT at 16.6 Cr vs 20.5 Cr, down 19.3%. Board approved a preferential issue of up to 16.21 lakh warrants to promoter entities at the higher of the applicable floor price or Rs 565 per warrant. The company continues to contest an income-tax demand of 62.7 Cr, with 10.3 Cr paid or proposed to be adjusted under protest.